| 郭明升,刘娟,郭英杰,等.阿托伐他汀联用强肝胶囊对脑梗死二级预防的效果分析[J].安徽医药,2021,25(1):148-152. |
| 阿托伐他汀联用强肝胶囊对脑梗死二级预防的效果分析 |
| Effect analysis of atorvastatin combined with Qianggan capsule on the secondary prevention for cerebral infarction |
| |
| DOI：10.3969/j.issn.1009?6469.2021.01.037. |
| 中文关键词: 脑梗死 二级预防 动脉粥样硬化 阿托伐他汀 强肝胶囊 析因分析 |
| 英文关键词: Cerebral infarction Secondary prevention Atherosclerosis Atorvastatin Qianggan capsule Factorial analysis |
| 基金项目:河北省医学科学研究重点课题计划(20181744)；邯郸市级科技研发计划(1823208019ZC) |
|
| 摘要点击次数: 1549 |
| 全文下载次数: 473 |
| 中文摘要: |
| 目的评估联用强肝胶囊和阿托伐他汀用于动脉粥样硬化性脑梗死(ACI)二级预防的效果。方法 2018年 6—11月冀中能源峰峰集团有限公司总医院收治住院的 120例急性脑梗死病人随机分为 10 mg对照组、 20 mg对照组、 10 mg观察组和 20 mg观察组，各 30例，均给予对应剂量的阿托伐他汀钙片，观察组均加用强肝胶囊，疗程 6个月。统计分析基线、治疗 3个月和 6个月血脂［三酰甘油(TG)、血总胆固醇(TC)和低密度脂蛋白胆固醇(LDL?C)］、丙氨酸氨基转移酶(ALT)、动脉内膜中层厚度(IMT)、 LDL?C达标率和 ACI复发率。结果 6个月时 TG水平，两个观察组低于 10 mg对照组［(1.49±0.31)和(1.36±0.31)分别比(1.74±0.36)mmol/L，P＜0.05］，20 mg观察组低于 20 mg对照组［(1.36±0.31)比(1.62±0.35)mmol/L，P＜0.05］； 3个月和 6个月时 TC和 LDL?C水平，两个 20 mg组低于 10 mg对照组［(3.91±0.57)和(3.64±0.53)分别比(4.31±0.63)mmol/L，(3.01±0.54)和(2.87±0.49)分别比(3.35±0.52)mmol/L，(2.26±0.49)和(2.11±0.42)分别比(2.58±0.52)mmol/L，(1.84±0.25)和(1.72±0.24)分别比(2.05±0.28)mmol/L，P＜0.05］20 mg观察组低于 10 mg观察组［(3.64±0.53)比(4.12±0.62)mmol/L，(2.87±0.49)比(3.22±0.51)mmol/L，(2.11±0.42)比(2.43±01)mmol/L，(1.72±0.24)比(1.96±0.27)mmol/L，P＜0.05］。 6个月时 IMT水平，两个 20 mg组低于两个 10 mg组［(1.07±0.21)和(1.04±0.22)分别比(1.21±0.16)和(1.20±0.18)mm，P＜0.05］。 3个月和 6个月时 ALT水平， 20 mg对照组高于其余 3组［(36.4±6.4)分别比(29.7±6.3)、(22.1±5.3)和(24.2±5.6)U/L，(25.9±4.1)分别比(22.8±4.4)、(18.4± .5，3.7)和(19.4±4.3)U/L，P＜0.01］10 mg对照组高于两个观察组［(29.7±6.3)分别比(22.1±5.3)和(24.2±5.6)U/L，(22.8±4.4)分别比(18.4±3.7)和(19.4±4.3)U/L，P，＜0.01］。析因分析:联合用药对 TG和 ALT有影响、联合用药和阿托伐他汀剂量对 ALT有交互作用(P＜0.05)。 LDL?C达标率:两个 20 mg组高于 10 mg对照组(43.3%和 66.7%分别比 6.7%，P′＜0.008 3)20 mg观察组高于 10 mg观察组(66.7%比 20.0%，P′＜0.008 3)。结论联用强肝胶囊可提高阿托伐他汀 ACI二级预防效果和安，全性。 |
| 英文摘要: |
| Objective To evaluate the effect of atorvastatin combined with Qianggan capsulesin the secondary prevention of ath? erosclerotic cerebral infarction(ACI).Methods A total of 120 patients with ACI admitted to Department of Neurology，General Hospital of Jizhong Energy Fengfeng Group Co.，Ltd from June 2018 to November 2018 were assigned to four groups(30 patients per group)10?mg control group(treated with 10 mg of atorvastatin)20?mg control group(treated with 20 mg of atorvastatin)，10? mgexperimen:talgroup(treatedwith10mgofatorvastatincombined，with Qianggan capsules)， and 20?mg experimental group(treated with 20 mg of atorvastatin combined with Qianggan capsules).The two experimental groups used the same dose of Qiang? gan capsules.The treatment course lasted for six months.Data on blood lipids［triglycerides(TG)，total blood cholesterol(TC)and low density lipoprotein cholesterol(LDL?C)］alanine aminotransferase(ALT)intima?media thickness(IMT)，LDL?C compliancerateandACIrecurrencerateatbaselineandthr，eemonthsandsixmonthsafterth，e treatment were collected for statistical analysis.Results At post?treatment six months，the TG levels in the two experimental groups were lower than those in 10?mg control group［(1.49±0.31)or(1.36±0.31)vs.(1.74±0.36)mmol/L，P＜0.05］，and that in 20?mg experimental groupwas lowerthan that in 20?mg control group［(1.36±0.31)vs.(1.62±0.35)mmol/L，P＜0.05］.At post?treatment three months and six months，the levels of TC and LDL?C in the two 20?mg groups were lower than those in 10?mg control group［(3.91±0.57)or(3.64±0.53)vs.(4.31±0.63) mmol/L，(3.01±0.54)or(2.87±0.49)vs.(3.35±0.52)mmol/L，(2.26±0.49)or(2.11±0.42)vs.(2.58±0.52)mmol/L，(1.84±0.25) or(1.72±0.24)vs.(2.05±0.28)mmol/L，P＜0.05］and those in 20?mgexperimental group were lower than those in 10?mg experi? mental group［(3.64±0.53)vs.(4.12±0.62)mmol/L，(，2.87±0.49)vs.(3.22±0.51)mmol/L，(2.11±0.42)vs.(2.43±0.51)mmol/L，(1.72±0.24)vs.(1.96±0.27)mmol/L，P＜0.05］.At post?treatment six months，the IMT levels in the two 20?mg groups were lower than those in the two 10?mg groups［(1.07±0.21)or(1.04±0.22)vs.(1.21±0.16)or(1.20±0.18)mm，P＜0.05］.At post?treatment three months and six months，the ALT levels in 20?mg control group were higher than those in the other three groups［(36.4±6.4) vs.(29.7±6.3)(22.1±5.3)or(24.2±5.6)U/L，(25.9±4.1)vs.(22.8±4.4)，(18.4±3.7)or(19.4±4.3)U/L，P＜0.01］，and those in 10?mgcontrolgro，up were higher than those in the two experimental groups［(29.7±6.3)vs.(22.1±5.3)or(24.2±5.6)U/L，(22.8±4.4)vs.(18.4±3.7)or(19.4±4.3)U/L，P＜0.01］.By the factorial analysis，the combination of drugs had significant effect on the levels of TG and ALT(P＜0.05)，and the drugs combination and atorvastatin dosage had interaction effect on the levels of ALT(P＜0.05).LDL?C compliance rate inthe two 20?mg groups were higher than those in 10?mg control group(43.3% or 66.7% vs. 6.7%， P′＜0.008 3)，and that in 20?mg experimental groupwas higherthan that in10?mg experimental group(66.7% vs. 20.0%，P′＜0.008 3).Conclusion Qianggan capsules combined use can improve the effect and safety of atorvastatin in the secondary preven? tion of ACI. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
